Cervical dilatation with prostaglandin analogues prior to vaginal termination of first trimester pregnancy in nulliparous patients

Abstract

Dilatation of the cervix with prostaglandin analogues prior to vaginal termination of pregnancy was attempted in 125 nulliparous women in the first trimester of pregnancy. The patients were divided into five groups (25 in each group) and given a single extra-amniotic dose of one of the following prostaglandin analogues 14–16 hours prior to the evacuation of the uterus by vacuum aspiration. (Group A) 15 (S) 15 methyl PGE 2 (free acid); (Group B) 15 (S) 15 methyl PGE 2 methyl ester; (Group C) 15 (S) 15 methyl PGF 2α (free acid); (Group D) 15 (S) 15 methyl PGF 2α methyl ester and(Group E) a mixture of 15 (S) 15 methyl PGE 2 methyl ester and 15 (S) 15 methyl PGF 2α methyl ester. Evacuation of the uterus without mechanical dilatation of the cervix was possible in 111 (90%) of the patients. In an additional 10 patients (8%) there was some degree of cervical dilatation and further mechanical dilatation could be performed easily. With the combination of 15 (S) 15 methyl PGE 2 methyl ester and 15 (S) 15 methyl PGF 2α methyl ester the incidence of gastrointestinal side effects and pyrexia were considerably reduced.